Blockchain In Pharmaceutical Supply Chain Market Size, Share, Opportunities, And Trends By Type (Public Blockchain, Private Blockchain, Hybrid Blockchain), By Application (Drug Traceability And Authentication, Supply Chain Transparency And Visibility, Counterfeit Drug Prevention, Inventory Management, Clinical Trials Management, Others), By End-User (Pharmaceutical Companies, Drug Distributors And Wholesalers, Pharmacies And Retailers, Healthcare Providers, Others), And By Geography - Forecasts From 2023 To 2028

The Blockchain in the Pharmaceutical Supply Chain market is anticipated to grow at a steady pace throughout the forecast period.

The blockchain pharmaceutical supply chain market is being transformed by blockchain technology, ushering in a new era of transparency, traceability, and efficiency. Blockchain's decentralised and immutable ledger allows secure and real-time monitoring of pharmaceutical items from producer to end-user in this dynamic industry, where medicine safety and authenticity are vital. Blockchain eliminates counterfeit medications and guarantees regulatory compliance by documenting each transaction, including sourcing, production, distribution, and sales. Furthermore, it allows for the rapid detection of supply chain concerns, decreasing product recalls and waste. The sector progressively adopts this disruptive technology to protect public health and optimise pharmaceutical operations.

Enhanced Supply Chain Transparency Enhances the Blockchain in Pharmaceutical Supply Chain Market Growth.

A significant growth factor for the blockchain in pharmaceutical supply chain market is increased supply chain transparency. According to a Deloitte poll, 60% of healthcare and life sciences executives cited supply chain transparency as a top benefit of blockchain implementationD. Stakeholders can trace and verify every transaction in real-time by exploiting blockchain's decentralised and immutable ledger, guaranteeing visibility and accountability at every level of the pharmaceutical supply chain. This openness not only allows for the early detection of possible problems or delays, but it also improves regulatory compliance and product authentication. Blockchain's capacity to improve supply chain transparency is likely to fuel considerable industry development as demand for safe and traceable pharmaceutical goods grows.

Prevention of Counterfeit Drugs in Blockchain in Pharmaceutical Supply Chain Market.

Counterfeit medicine prevention is a big growth element in the Blockchain in Pharmaceutical Supply Chain Market. According to the World Health Organisation (WHO), counterfeit medications account for around 10% of the worldwide pharmaceutical industry, posing major health concerns. Blockchain's immutable and transparent ledger provides end-to-end pharmaceutical product traceability, making it extremely efficient in countering counterfeit medications. Blockchain technology fosters trust and confidence among customers and regulatory authorities by assuring product authenticity and origin verification, hence pushing its adoption in the pharmaceutical business.

Efficient Track and Trace Capabilities Boosts the Blockchain in Pharmaceutical Supply Chain Market Size.

Efficient track and trace capabilities are a key driver of growth in the blockchain in pharmaceutical supply chain market.. The decentralised and tamper-proof ledger of blockchain enables real-time monitoring and recording of goods movement from manufacture through distribution and sale. This increased visibility allows for the rapid discovery of supply chain concerns, minimises the danger of counterfeit medications, and enhances overall supply chain efficiency, propelling blockchain adoption in pharmaceutical track and trace applications.

North America is the Market Leader in the Blockchain in Pharmaceutical Supply Chain Market.

North America has emerged as the market leader for blockchain in pharmaceutical supply chain market. The region's significance may be linked to its superior healthcare infrastructure, strong focus on pharmaceutical laws, and widespread usage of blockchain technology. Furthermore, North America is home to several notable pharmaceutical businesses and technology pioneers who are actively investigating blockchain technologies to improve supply chain security and efficiency. The region's dedication to ensuring drug safety, combating counterfeit products, and improving supply chain transparency has resulted in significant investment and interest in implementing blockchain solutions in the pharmaceutical industry, putting North America at the forefront of this transformative market.

Facilitation of Smart Contracts for Transactions in Blockchain in Pharmaceutical Supply Chain Market.

The use of smart contracts to facilitate transactions is a major growth element in the blockchain in pharmaceutical supply chain market. The distributed ledger technology of blockchain enables the construction of self-executing smart contracts, which automate numerous supply chain transactions without the use of middlemen. These contracts impose set norms and conditions on stakeholders, guaranteeing secure and transparent interactions. According to a Capgemini survey, 87% of organisations that implemented blockchain reported increased contract administration efficiency. Smart contracts improve confidence and accountability in the pharmaceutical supply chain by streamlining payment processing, inventory management, and regulatory compliance.

Key Developments:

• In July 2020, Chronicled and Deloitte announced a partnership today to deliver blockchain-powered solutions to the life sciences and health care industries. The cooperation will use technology and solutions powered by Chronicled's MediLedger Network, a blockchain-enabled network for the life sciences industry, to improve interoperability, security, and efficiency in revenue management and pharmaceutical supply chain procedures.
• In August 2023, TraceLink Inc., the leading digital network platform company connecting more than 290,000 healthcare and life sciences entities through its B2N Integrate-OnceTM network to enable end-to-end product orchestration, partnered with Value Drug Company, a wholesale distribution and retail/speciality pharmacy services provider, to create a complete commercial, solution, and services programme for independent pharmacies to satisfy forthcoming difficult DSCSA standards.

Company Products:

• Drug Authentication: The blockchain technology provided by Blockpharma enables pharmaceutical makers and distributors to authenticate pharmaceuticals and verify their provenance across the supply chain. The technology secures the legality of pharmaceutical items by documenting each transaction on an immutable ledger, preventing counterfeit pharmaceuticals from accessing the market.
• SAP Information Collaboration Hub for Life Sciences (ICH): This blockchain-enabled network allows pharmaceutical makers, distributors, and other stakeholders to communicate information in a safe and easy manner. It allows for real-time tracking and tracing of pharmaceutical items from raw materials to end-users, improving supply chain transparency and combating counterfeit pharmaceuticals.
• MoleScope Dermatology Device: This blockchain-based approach allows pharmaceutical producers, distributors, and healthcare practitioners to collaborate and share information. It enables pharmaceutical product traceability from beginning to finish, assuring regulatory compliance and preventing counterfeit pharmaceuticals from entering the supply chain.
• MediLedger: Chronicled's MediLedger is a blockchain-based technology aimed to improve the integrity and efficiency of the pharmaceutical supply chain. It offers real-time pharmaceutical product tracking and verification, assuring authenticity and preventing counterfeit pharmaceuticals from entering the supply chain.

Segmentation:

• By Type
  • Public Blockchain
  • Private Blockchain
  • Hybrid Blockchain           
• By Application
  • Drug Traceability And Authentication
  • Supply Chain Transparency And Visibility
  • Counterfeit Drug Prevention
  • Inventory Management
  • Clinical Trials Management
  • Others        
• By End-User
  • Pharmaceutical Companies
  • Drug Distributors And Wholesalers
  • Pharmacies And Retailers
  • Healthcare Providers
  • Others                    
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain    
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Taiwan
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Sources

2.3. Research Design

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. BLOCKCHAIN IN PHARMACEUTICAL SUPPLY CHAIN MARKET, BY TYPE

5.1. Introduction

5.2. Public Blockchain

5.3. Private Blockchain

5.4. Hybrid Blockchain           

6. BLOCKCHAIN IN PHARMACEUTICAL SUPPLY CHAIN MARKET, BY APPLICATION

6.1. Introduction

6.2. Drug Traceability and Authentication

6.3. Supply Chain Transparency and Visibility

6.4. Counterfeit Drug Prevention

6.5. Inventory Management

6.6. Clinical Trials Management

6.7. Others        

7. BLOCKCHAIN IN PHARMACEUTICAL SUPPLY CHAIN MARKET, BY END-USER

7.1. Introduction

7.2. Pharmaceutical Companies

7.3. Drug Distributors and Wholesalers

7.4. Pharmacies and Retailers

7.5. Healthcare Providers

7.6. Others                    

8. BLOCKCHAIN IN PHARMACEUTICAL SUPPLY CHAIN MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Spain

8.4.6. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia 

8.6.6. Taiwan

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. IBM Corporation

10.2. SAP SE

10.3. Chronicled Inc.

10.4. Ambrosus (Now part of Parity Technologies)

10.5. Chronicled, Inc.

10.6. MediLedger Project

10.7. FarmaTrust

10.8. Blockpharma

10.9. Chainvine

10.10. Genpact         

Ibm Corporation

Sap Se

Chronicled Inc.

Ambrosus (Now Part Of Parity Technologies)

Chronicled, Inc.

Mediledger Project

Farmatrust

Blockpharma

Chainvine

Genpact